Ignet

Gene Information

Gene symbol: F2

Gene name: coagulation factor II (thrombin)

HGNC ID: 3535

Related Genes

#	Gene Symbol	Number of hits
1	CCL2	1 hits
2	F2R	1 hits
3	F2RL2	1 hits
4	F2RL3	1 hits
5	F5	1 hits
6	GPR172A	1 hits
7	GPR172B	1 hits
8	MARK2	1 hits
9	NR1I2	1 hits
10	SERPINE1	1 hits
11	VEGFA	1 hits

Related Sentences

#	PMID	Sentence
1	29110957	The kidney expresses protease-activated receptor-1 (PAR-1).
2	29110957	PAR-1 is known as a thrombin receptor, but its role in kidney injury is not well understood.
3	29110957	Pathological analysis showed that Q94 treatment significantly attenuated periodic acid-Schiff and desmin staining, indicators of podocyte injury, and also decreased glomerular levels of podocin and nephrin.
4	29110957	In addition, both Q94 and Rox4560 suppressed the doxorubicin-induced increase in activities of caspase-9 and caspase-3 in podocytes.
5	28424276	Using receptor-blocking antibodies and activation peptides, we determined that thrombin-mediated injury depended upon interactions between protease-activated receptor 3 and protease-activated receptor 4 in human podocytes, and between protease-activated receptor 1 and protease-activated receptor 4 in rat podocytes.
6	28424276	Using receptor-blocking antibodies and activation peptides, we determined that thrombin-mediated injury depended upon interactions between protease-activated receptor 3 and protease-activated receptor 4 in human podocytes, and between protease-activated receptor 1 and protease-activated receptor 4 in rat podocytes.
7	28424276	Proximity ligation and coimmunoprecipitation assays confirmed thrombin-dependent interactions between human protease-activated receptor 3 and protease-activated receptor 4, and between rat protease-activated receptor 1 and protease-activated receptor 4 in cultured podocytes.
8	28424276	Proximity ligation and coimmunoprecipitation assays confirmed thrombin-dependent interactions between human protease-activated receptor 3 and protease-activated receptor 4, and between rat protease-activated receptor 1 and protease-activated receptor 4 in cultured podocytes.
9	27733370	Protease-activated receptors (PARs) are members of a well-known family of transmembrane G protein-coupled receptors (GPCRs).
10	27733370	Protease-activated receptors (PARs) are members of a well-known family of transmembrane G protein-coupled receptors (GPCRs).
11	27733370	Four PARs have been identified to date, of which PAR1 and PAR2 are the most abundant receptors, and have been shown to be expressed in the kidney vascular and tubular cells.
12	27733370	Four PARs have been identified to date, of which PAR1 and PAR2 are the most abundant receptors, and have been shown to be expressed in the kidney vascular and tubular cells.
13	27733370	The receptors are activated by endogenous serine proteases, such as thrombin (acts on PARs 1, 3, and 4) and trypsin (PAR2).
14	27733370	The receptors are activated by endogenous serine proteases, such as thrombin (acts on PARs 1, 3, and 4) and trypsin (PAR2).
15	27733370	Clinical studies further demonstrated that the concentration of urinary thrombin is associated with glomerulonephritis and type 2 diabetic nephropathy; thus, molecular and functional mechanisms of PARs activation can be directly involved in renal disease progression.
16	27733370	Clinical studies further demonstrated that the concentration of urinary thrombin is associated with glomerulonephritis and type 2 diabetic nephropathy; thus, molecular and functional mechanisms of PARs activation can be directly involved in renal disease progression.
17	27733370	We briefly discuss here the recent literature related to activation of PAR signaling in glomeruli and the kidney in general and provide some examples of PAR1 signaling in glomeruli podocytes.
18	27733370	We briefly discuss here the recent literature related to activation of PAR signaling in glomeruli and the kidney in general and provide some examples of PAR1 signaling in glomeruli podocytes.
19	21389321	In diabetic patients, the FVL mutation, but not the plasminogen activator inhibitor-1 4G/5G polymorphism, is associated with reduced albuminuria, which is consistent with a nephroprotective role of low but sustained thrombin generation.
20	21389321	In diabetic patients, the FVL mutation, but not the plasminogen activator inhibitor-1 4G/5G polymorphism, is associated with reduced albuminuria, which is consistent with a nephroprotective role of low but sustained thrombin generation.
21	21389321	These results identify a nephroprotective function of low but sustained thrombin levels in FVL carriers, supporting a dual, context-dependent function of thrombin in chronic diseases.
22	21389321	These results identify a nephroprotective function of low but sustained thrombin levels in FVL carriers, supporting a dual, context-dependent function of thrombin in chronic diseases.
23	18622025	Thrombin enhances the production of monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 in cultured rat glomerular epithelial cells.
24	14978158	Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties.
25	14978158	Podocytes produce endothelial factors, including angiopoietin 1 (ang1), and vascular endothelial growth factor (VEGF), whereas GEnC express their respective receptors Tie2 and VEGFR2 in vivo.
26	14978158	Responses to a cAMP analogue and thrombin were examined before those to ang1 and VEGF.
27	14978158	Results confirmed the endothelial origin of GEnC and their expression of Tie2 and VEGFR2.
28	14978158	Ang1 increased TEER by 11.4 Omega/cm(2) and reduced protein passage by 45.2%, whereas VEGF reduced TEER by 12.5 Omega/cm(2) but had no effect on protein passage.